This study investigates whether the experimental drug BMS-986488, used alone or combined with other treatments, is safe and effective in treating advanced malignant tumors (cancer that is spreading and cannot be removed by surgery). Participants must be at least 18 years old and have specific types of cancer, such as certain lung, kidney, and ovarian cancers that have specific mutations. The study uses a scale called the Eastern Cooperative Oncology Group (ECOG) Performance Status to assess how well participants can perform daily activities. It ranges from 0 (fully active) to 5 (dead). Participants need a score of 0 or 1, meaning they are fully active or limited in strenuous activity but able to carry out light work.

• The study length and number of visits are not specified, so be prepared for ongoing participation.
• Participants with untreated brain cancer or severe heart conditions cannot join.
• Some participants will receive a combination treatment, requiring additional eligibility checks.

Remember, joining a study means you may receive new treatments before they are widely available, but it also includes risks and side effects.